NCT02536742: Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer

NCT02536742
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Patient must also have ER+ tumor(s)
Exclusions: Patients with known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis or leptomeningeal disease 
https://ClinicalTrials.gov/show/NCT02536742

Comments are closed.

Up ↑